Esmolol Versus Dexmedetomidine During Intracranial Procedures
|ClinicalTrials.gov Identifier: NCT02563288|
Recruitment Status : Unknown
Verified July 2017 by Asouhidou Irene, George Papanicolaou Hospital.
Recruitment status was: Recruiting
First Posted : September 30, 2015
Last Update Posted : July 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Intracranial Aneurysm Intracranial Neoplasms||Drug: Esmolol Drug: Dexmedetomidine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures|
|Study Start Date :||August 2016|
|Estimated Primary Completion Date :||August 2017|
|Estimated Study Completion Date :||October 2017|
Active Comparator: Esmolol
Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.
effect of esmolol on intraoperative sympathetic control and on extubation conditions.
Other Name: b adrenergic antagonist
Active Comparator: Dexmedetomidine
Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.
effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
Other Name: alpha adrenergic agonist
- Systolic arterial pressure- mean arterial pressure (mmHg) [ Time Frame: every 15minutes, starting from the induction in anesthesia through surgery completion and up to first 24 postoperative hours. ]Status of patients during emerge from anaesthesia after intracranial surgery
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02563288
|Contact: Irene Asouhidou, MD, PhDemail@example.com|
|Contact: Dimitris Zosimidis, MDfirstname.lastname@example.org|
|George Papanikolaou General Hospital||Recruiting|
|Thessaloniki, Greece, 55133|
|Contact: Irene Asouhidou, MD, PhD 00302310452560 email@example.com|